Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2Breast 2Thoracic 1Sarcoma 1Other neoplasm 1NET 1Myeloid 1Endocrine 1CNS 1

Conditions

Advanced Lung Neuroendocrine Tumor 1

Interventions

lutetium Lu 177 dotatate 7Specimen Handling 7Magnetic Resonance Spectroscopy 7gallium Ga 68 dotatate 3cabozantinib 3X-Rays 3Everolimus 3Sunitinib 2Phantoms, Imaging 23-aminopyridine-2-carboxaldehyde thiosemicarbazone 2romidepsin 1peposertib 1pembrolizumab 1pazopanib 1olaparib 1fludarabine 1belinostat 1aldesleukin 1Sorafenib 1Salts 1Photons 1Octreotide 1Nivolumab 1Lactones 1Ipilimumab 1Introns 1Interferon alpha-2 1Immunoglobulin G 1Fluorodeoxyglucose F18 1Etoposide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Photons × NET × Clear all
NCT04665739 2026-05-13

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
70 enrolled
EndocrineNET

Advanced Lung Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡